Biocept (NASDAQ:BIOC) is scheduled to post its quarterly earnings results after the market closes on Monday, August 12th.
Biocept (NASDAQ:BIOC) last posted its quarterly earnings data on Wednesday, May 8th. The medical research company reported ($0.61) earnings per share (EPS) for the quarter. Biocept had a negative net margin of 695.85% and a negative return on equity of 338.61%. The business had revenue of $1.02 million for the quarter.
BIOC traded down $0.01 during trading hours on Tuesday, reaching $1.01. 975 shares of the company’s stock traded hands, compared to its average volume of 456,919. The company’s 50-day moving average price is $1.05. Biocept has a 52-week low of $0.66 and a 52-week high of $4.75. The company has a debt-to-equity ratio of 0.10, a current ratio of 2.72 and a quick ratio of 2.63. The firm has a market capitalization of $19.16 million, a price-to-earnings ratio of -0.11 and a beta of 1.93.
Biocept Company Profile
Biocept, Inc, an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms.
Read More: What is a death cross?
Receive News & Ratings for Biocept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept and related companies with MarketBeat.com's FREE daily email newsletter.